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recurrence and 15 patients had bilateral recurrence, median time
to recurrence was 3.2 years and median follow-up time was
6.2 years. A weak correlation was observed between cytoplasmic
pAkt and cytoplasmic pNF-kB (cc 0.166, P = 0.001). Cytoplasmic
pAkt expressionwas associatedwith decreased time to recurrence
(p = 0.025) and was significantly higher in ER negative tumours
compared to ER positive (p = 0.004). When cohort was split by PR
status, the associationwith decreased time to recurrence and cyto-
plasmicpAktwaspotentiated (p = 0.008).CytoplasmicpAktexpres-
sioncorrelatedsignificantlywithnuclearpAktexpression (cc0.696,
p < 0.001). Nuclear pAkt expression was also associated with
decreased time to recurrence (p = 0.043). In addition the observa-
tion with nuclear pAkt was potentiated in ER negative tumours
(p = 0.037) andPRnegative tumours (p = 0.002). No significant corre-
lation with time to recurrence was observed for NF-kB or pNF-kB.
Conclusion: In the current cohort pAkt expression was associ-
ated with recurrence, however this was independent of the NF-
kB cascade.
doi:10.1016/j.ejcsup.2010.06.015
O-15 UPREGULATION OF THE ESTROGEN PATHWAY IN ENDO-
CRINE SENSITIVE BREAST CANCER CELLS WITH HERCEPTIN
TREATMENT
J.G. Solon, D. Collins, M. McIlroy, A.D.K. Hill, L. Young. Endocrine
Oncology Research Group, Royal College of Surgeons in Ireland, Ireland
Breast cancer is the leading cause of cancer-related deaths in
women in Ireland. Receptor crosstalk has been implicated in the
development of resistance to therapies and cancer relapse. We
have previously shown that treatment of endocrine insensitive
or independent breast cancer cells with herceptin repressed tran-
scriptional activity of the oncogene c-Myc through SMRT activity.
However, endocrine sensitive breast cancer cells with low levels
of HER2 receptor showed hyperactivation of the estrogen/steroid
pathway through recruitment of the cointegrator protein CBP.
The aim of this study was to demonstrate the activation of the
steroid pathway in endocrine sensitive breast cancer cells treated
with herceptin using the classical ER target gene pS2 as a marker
of activity.
MCF-7cells (highER, lowHER2, endocrinedependent) andLCC-1
cells (highER,highHER2, endocrine independent)were treatedwith
estradiol (E2), tamoxifen and herceptin. Semi-quantitative RT-PCR
and qRT- PCR was performed to quantify pS2 mRNA levels. The
impact of treatments on pS2 promoter activity was then assessed.
Cells were transfected with the expression vector pSG5- ERa and
the luciferse reporter plasmid pGL3-pS2 promoter and the level of
transcriptional activity recorded. Increases in pS2 mRNA were
found inMCF-7 cells treatedwithherceptinbutnot LCC-1 cells. This
was replicated at a transcriptional level through luciferase assay.
We have shown that at mRNA and transcriptional levels treat-
ment of MCF-7 cells with herceptin results in upregulation of the
steroid pathway. We are currently conducting further molecular
studies to further elucidate the signalling pathways involved.
doi:10.1016/j.ejcsup.2010.06.016
O-16 JAMA-A: A HOPE FOR BREAST CANCER THERAPY?
Gozie Offiah. Department of Surgery, Royal College of Surgeons,
Ireland
Background: Breast cancer is a very prevalent disease with
most cancers originating in the milk ducts, composed of a layer
of polarized epithelial cells. Loss of polarity is a hallmark of
many cancers including breast. We recently showed a novel
correlation between over-expression of the cell adhesion pro-
tein JAM-A and poor prognosis in invasive breast cancer
patients.1
Aim: To determine whether JAM-A regulates proliferation and
polarity in breast cancer cells in a manner explaining its associa-
tion with aggressive cancer phenotypes.
Materials and methods: Proliferation assays were carried out
using the isogenic breast cancer cell line series HMT-3522, of S1
(normal) and T42 (invasive) cells in the presence of an inhibitory
JAM-A antibody. Both cell types were grown in a 3-dimensional
(3D) extracellular matrix culture model. Cultures were exposed
to inhibitory JAM-A antibody to determine the consequences
of antagonising JAM-A function for 3D polarization and
differentiation.
Results: We observed significant anti-proliferative effects in
both S1 and T42 cells exposed to JAM-A inhibitory antibody over
time. Both S1 and T42 cells treated with JAM-A inhibitory anti-
body showed significant reductions in 3D spheroidal diameter rel-
ative to IgG-treated cells (p < 0.05), correlating with observed anti-
proliferative effect. Furthermore, invasive T4-2 cells in 3D culture
treated with JAM-A inhibitory antibody exhibited a partial nor-
malization of phenotype.
Conclusions: Our results indicate that JAM-A inhibition
decreases proliferation and promotes polarisation. Therefore,
we speculate that pharmacological antagonism of JAM-A in
breast cancer patients may offer a novel therapeutic opportunity.
Reference:
1. McSherry EA, McGee SF, Jirstrom K, Doyle EM, Brennan DJ,
Landberg G, et al. JAM-A expression positively correlates with
poor prognosis in breast cancer patients. Int J Cancer
2009;125(6):1343–51.
doi:10.1016/j.ejcsup.2010.06.017
O-17 BORDERLINE HER2 PROTEIN POSITIVE BREAST CANCERS
HAVE SIMILAR PATIENT OUTCOME REGARDLESS OF HER2 GENE
AMPLIFICATION STATUS
F.F.T. Barros, M. Aleskandarany, E. Rakha, S.L. Watts, D.G. Powe,
I.O. Ellis, A.R. Green. Division of Pathology, Nottingham University
Hospitals and University of Nottingham, Nottingham, UK
HER2 plays an important role in breast cancer progression and
provides predictive and prognostic information. However, prog-
nostic information provided by IHC expression categories and
prognostic value added by using in situ hybridisation (ISH) in bor-
derline cases remains unclear.
6 EJC SUPPLEMENTS 8 (2010) 1–36
